COMMUNIQUÉS West-GlobeNewswire

PHAXIAM Therapeutics annonce la validation d’une nouvelle étude de phase 2, PHAGOSCARPA, sponsorisée par un investigateur
09/10/2024
Étude de phase 2 sponsorisée par l'Assistance Publique – Hôpitaux de Paris (AP-HP) dans le cadre du Programme Hospitalier de Recherche Clinique (PHRC) Évaluation de l'efficacité d'un traitement local avec les phages [...]
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
09/10/2024
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant [...]
Oncovita appoints Stéphane Altaba as Chief Executive Officer
09/10/2024
Paris, France, October 9 th , 2024 - Oncovita, a biotechnology company specializing in the development of therapeutic cancer vaccines and prophylactic vaccines, today announced the appointment of Dr. Stéphane Altaba as [...]
Health-ISAC Partners with Booz Allen Hamilton to Strengthen Global Cybersecurity in Healthcare
09/10/2024
ORLANDO, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Health-ISAC Partners with Booz Allen Hamilton to Strengthen Global Cybersecurity in Healthcare Health Information Sharing and Analysis Center (Health-ISAC), the non- [...]
USOSM Adds Three Partner Practices to Best-in-Class Network of Oral and Maxillofacial Surgeons
09/10/2024
IRVING, Texas, Oct. 09, 2024 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM) has secured new partnerships with three oral and maxillofacial surgeons in three states: California, Alabama and Tennessee. The new [...]
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
09/10/2024
-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: [...]
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
09/10/2024
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a [...]
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
09/10/2024
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities BERKELEY HEIGHTS, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Cyclacel [...]
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
09/10/2024
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
The largest family medicine gathering in Canada takes place in Vancouver in November
09/10/2024
FMF 2024: The best in family medicine education and networking MISSISSAUGA, Ontario, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Family doctors from across Canada and around the world will be converging on the Vancouver [...]
Le plus grand rassemblement de médecins de famille au Canada aura lieu à Vancouver en novembre
09/10/2024
FMF 2024 : Une formation de qualité et des occasions de réseautage MISSISSAUGA, Ontario, 09 oct. 2024 (GLOBE NEWSWIRE) -- Les médecins de famille de partout au Canada et des quatre coins du monde se donnent rendez-vous [...]
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
09/10/2024
SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Inmagene to Host Virtual KOL Event on the Inhibition of the OX40/OX40L Signaling in the Treatment of Atopic Dermatitis and Alopecia Areata
09/10/2024
SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory (I&I [...]
Syneos Health Appoints Costa Panagos as Chief Executive Officer
09/10/2024
Colin Shannon Appointed Executive Chairman Seasoned Executive Further Strengthens Company’s Leadership Team MORRISVILLE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Syneos Health ® , a leading fully integrated [...]
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
09/10/2024
Live webcast fireside chat on Wednesday, October 16th at 12:30 PM ET OCALA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that Tom Equels, [...]
Verana Health Introduces Qdata Explorer in Advance of 2024 American Academy of Ophthalmology Annual Meeting
09/10/2024
The innovative platform accompanies the launch of Qdata Retinitis Pigmentosa for life sciences and the development of Practice Insights for clinicians SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Today, Verana [...]
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders
09/10/2024
Patients, providers, and public are invited to help save lives by sharing messages and materials PASADENA, Calif. and CELEBRATION, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- The National Urea Cycle Disorders Foundation ( [...]
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
09/10/2024
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects – – Poster presentation taking place on Thursday, [...]
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
09/10/2024
Sonnet to receive $1.0 million in upfront payment and up to an additional $1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India market Alkem to fund [...]

Pages